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VLA2 integrin expression in breast carcinomas
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Summary VLA2 is thought to be involved in the metastatic process in malignant tumours, in particular in carcinomatous cell adhesion to
vessel basement membrane. VLA2 expression was immunohistochemically investigated in 204 breast carcinomas. Frozen tissue sections
were probed with monoclonal anti-VLA2 using automated (Ventana ES 320 System) and quantitative (SAMBA 2005 image processor)
immunoperoxidase. A positive anti-VLA2 immunoreaction was observed in 48 tumours (23.5%), within epithelial carcinomatous cells. The
VLA2-positive surface in tumours varied from 3% to 20% (mean 8.75, S.D. 7.17) and was correlated with histoprognostic indicators and
tumour expression of various antigens detected using the same method as that for VLA2. The results show that VLA2 immunoexpression was
independent of the tumour size, grade, type and aneuploidy, and of the nodal status. VLA2 significantly correlated with ELAM, VCAM, VLA3
and P-glycoprotein (P-gp) (P < 0.01) and inversely correlated with cathepsin D (P < 0.001), but was independent of Ki67/MIB1, p53, bcl-2,
c-erbB-2, E cadherin, CD44v, CD31, cestrogen and progesterone receptors' (ER, PR) antigenic sites and pS2. The exact role, if any, of VLA2
in tumour cell dissemination remains to be elucidated and the clinical relevance of VLA2 immunodetection in breast carcinomas requires
further investigation of the correlation between VLA2 immunocytochemical expression and patients' outcome and response to chemotherapy.
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The integrins are heterodimers consisting of non-covalently asso-
ciated ox and P subunits that mediate cell adhesion. As originally
described (Hynes, 1987), integrins were divided into three
subfamilies, each with a common 3 subunit capable ofassociating
with a specific group of ox subunits. In fact, there are several
different : subunits, and x subunits can combine with more than
one subunit (see review in Pignatelli, 1994).
Because of the complexity of the integrins family, it proves
useful to group integrins according to their cell binding activity.
Integrins can be segregated into three groups: those that function
as cell-cell adhesion molecules, those that bind primarily to the
major constituents of the basement membrane (i.e. collagen and
laminin) and those that bind primarily to the extracellular matrix
proteins found during early development, inflammation and
wound healing (i.e. fibronectin, fibrinogen vitronectin and
thrombospondin) (see review in Albelda, 1993).
The a, ,B integrin (or VLA2, very late antigen) is a receptor
(145-kDa molecule) for collagen and laminin that is expressed in
many tumour cell lines (see review in Albelda, 1993). In addition,
VLA1 is widely expressed in normal tissue and its polarized distri-
bution in various epithelial cells suggests that they may signifi-
cantly act upon the control of cellular growth and differentiation
(De Strooper et al, 1989; Zutter and Santoro, 1990; Ruoslahi,
1991). Also VLA, is probably implicated in the complex multistep
Received 11 August 1997
Revised 19 December 1997
Accepted 9 January 1998
Correspondence to: C Charpin, Department of Pathology ('Oncogenese des
tumeurs solides'), Faculte de Medecine Timone, 27 Bd Jean Moulin, 13385
Marseille Cedex 5, France
process of tumour invasion and metastasis in vitro and in vivo
(Zetter, 1993). The rhabdomyosarcoma cell line, a poorly
metastatic line that does not express VLA2, increases metastatic
potential after either tail vein or subcutaneous inoculation when
transfected with a, , cDNA (Chan et al, 1991; Zetter, 1993),
suggesting that increased adhesion of tumour cells to subendo-
thelial basement membrane components results in increased
metastatic potential. In contrast, the down-regulation of VLA, is
observed in poorly differentiated or larger tumours of the colon
(Pignatelli et al, 1991a), liver (Patriarca et al, 1993), skin (Stamp
et al, 1991) and breast (Zutter et al, 1990; Pignatelli et al, 1991b;
Arihiro et al, 1993), and in prostate carcinomas (Bonkhoff et al,
1993) and melanomas (Schadendorf et al, 1993), suggesting that
reduced VLA2 expression may be an indicator ofpredisposition to
the development of metastases.
However, adhesion of tumour cells to basement membrane
components is not the only process thought to be involved in
tumour growth and metastasis (Zutter and Santoro, 1990; Albelda,
1993; Pignatelli et al, 1994). Tumour metastasis requires: firstly,
the release of the cells from the primary tumour with decreased
cell-cell adhesion and reduced cell adhesion to epithelial base-
ment membrane; secondly, the migration oftumour cells and their
adhesion to extracellular matrix; and, finally, their penetration into
the vessels' walls and their arrest in the microcirculation of the
distant organs, and adhesion to endothelial cells and vessel base-
ment membrane before extravasation (Zutter and Santoro, 1990;
Albelda, 1993; Pignatelli et al, 1994).
In this study, ourgoal was to investigate the relationship between
the tumour cells' capacity to bind to basement membrane mole-
cules, reflected by VLA, expression, and other steps of the
metastatic process involving several other adhesive molecules or
proteases, including E cadherin (cell-cell adhesion), cathepsin D
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(facilitating the migration in extracellular matrix), VLA3 and CD44
(adhesion to extracellular components), CD31 (angiogenesis),
VCAM and ELAM (endothelial cell activation). We investigated a
series of 204 breast carcinomas using automated immunohisto-
chemistry (Ventana ES 320 device) and quantification of the
immunoprecipitates by processing digitized microscopic images
(SAMBA 2005 System). In addition, our objective was to investi-
gate the prognostic significance of VLA, immunohistochemical
expression in tumour cells by correlating the results with current
histoprognostic indicators (tumour size, grade, type and axillary
node status) and with immunohistochemical indicators of high
degree ofcell proliferation (MIBl/Ki67, p53, bcl-2, c-erbB-2).
MATERIALS AND METHODS
Source of tissue samples
The specimens were surgically obtained from 204 patients with
breast carcinomas, from January 1993 to May 1994. Mean age was
56.4 years (range 32-83 years, median 56 years). For all patients,
surgical resection was the primary treatment, and none received
irradiation or chemotherapy preoperatively. Surgical specimens
were fixed in Bouin fixative, paraffin embedded and haema-
toxylin-eosin- and saffronin-stained for routine microscopic diag-
nosis. Samples for immunodetection were taken from the
representative cancerous lesions by pathologists, in the same way
as for the sample used for the intraoperative microscopic diagnosis
on frozen sections. Tissue samples for immunodetections were
promptly dipped in liquid nitrogen and stored frozen at -800C in
the tumour library ofthe laboratory.
Histopathological features
Tumour sizes ranged from 4 to 80 mm (mean 17.9; s.d. 12.24). In
196 of 204 cases, axillary lymph node resection was performed
and 62% ofpatients (n = 121) were node positive and 38% (n = 75)
were node negative.
All carcinomas were invasive. Invasive ductal carcinomas
accounted for 74% (145 of 204), lobular carcinomas for 17% (38
of204) and invasive carcinomas ofother types for 9% (20 of204).
Tumours were graded according to Elston's grading system
(Elston et al, 1991). Grade I tumours accounted for 22% (45 of
204), grade II for 54% (109 of 204) and grade III for 24% (49 of
204). Carcinomas were also graded according to Le Doussal's
modified Bloom's grading system (Le Doussal et al, 1989) in five
grades: 8% of grade I, 30% of grade II, 31% of grade III, 27% of
grade IV and 4% ofgrade V. Tumours were also ranked according
to the Nottingham prognostic index (Galea et al, 1992), which
ranged from 2.1 to 8 (mean 4.1; s.d. 1.22). Tumours were aneu-
ploid in 58% of the cases (97/168), with a variable degree of
hyperploidy (mean 5.4%, range 0-60%) (cell imprints, Feulgen
staining, image analysis) (Charpin et al, 1990, 1992).
Immunohistological staining procedures
Antibody sources
Anti-human VLA, (150-kDa integrin oc2 chain, anti-CD29b)
mouse monoclonal (immunoglobulin G1) antibody (clone Gi9)
was purchased from Immunotech (Marseille, France) and used
diluted at 1:500 (Arihiro et al, 1993; Bonkhoff et al, 1993). The
other monoclonal antibodies used were all commercially available
Figure 1 VLA2 expression in frozen section (anti-VLA2, Immunotech)
obtained using automated (Ventana) and quantitative (SAMBA)
immunoperoxidase. Positive VLA2 immunostaining is observed in epithelial
cells of grade 2 breast ductal carcinomas
Figure 2 VLA2 expression in frozen section (anti-VLA2 Immunotech)
obtained using automated (Ventana) and quantitative (SAMBA)
immunoperoxidase. Positive VLA2 immunostaining is observed in epithelial
cells of grade 3 breast ductal carcinomas
Figure 3 VLA2 expression in frozen section (anti.VLA2 lmmunotech)
obtained using automated (Ventana) and quantitative (SAMBA)
immunoperoxidase. Positive VLA2 immunostaining is observed in tumour
cells of lobular breast carcinomas
and were used as described previously (Charpin et al, 1988a, 1994,
1995b, 1997a-d): MIBI, anti-CD31, anti-VCAM (clone lGl),
ELAM (clone 1.2 B6), VLA, (clone Gi9) (Immunotech), anti-p53
(Oncogene Science, Paris, France), anti-c-erbB-2 (Biogenex
Menarini, Chevilly Larue, France), anti-cathepsin D (CisBio
International, Gif sur Yvette, France), anti-P-glycoprotein (P-gp)
(clone JSB1-N, Tebu, Le Perray en Yvelines, France), anti-ER and
-PR (Abbott kits, Rungis, France), anti-pS2 (Cisbio, France), anti-
CD44 V6 (clone 2F10, RD System Europe, Abingdon, Oxon,
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Figure 4 Distribution of positive VLA2 surfaces evaluated (%) on tissue
sections by computer-assisted (SAMBA) analysis of digitized microscopic
coloured images
Table 1 VLA2 expression and clinicopathologic data
VLA2=0 VLA2 >0
40
UK), anti-E cadherin (clone HECD1, RD System), anti-bcl-2
(clone 124) (Dako, 78196 Trappes, France).
Automated immunohistochemistry
Automated immunohistochemistry was used for all the mono-
clonal antibodies, except for anti-E cadherin (LSAB kits, Dako)
(Charpin et al, 1997c) and anti-ER and anti-PR (Abbott Kits)
(Charpin et al, 1988b) and was performed on consecutive sections
(4 gm thick) with avidin-biotin-peroxidase complex on Ventana
320 device (Grogan et al, 1993, 1995) (Ventana) Ventana kits
(Ventana Systems, Strasbourg, France) including aminoethylcar-
bazol reagent. Sections were counterstained with haematoxylin,
dehydrated and mounted in glycergel.
Image processing and statistical analysis
Images of immunoprecipitates were obtained using an Axiophot
microscope (Zeiss, Le Pecq 78230, France) and a 3CCD camera
(Sony, Paris, France) and were then processed by an image
analysis system (SAMBA 2005, Alcatel-TITN, Grenoble, France)
(Charpin et al, 1997a-d). The two parameters of densitometric
analysis, percentage of immunostained surface (compared with
counterstained surface) and mean optical density (MOD), which
reflects the staining intensity (on SAMBA arbitrary units scale of
0-255) were obtained as previously reported (Charpin et al, 1988a
and b, 1994, 1995a and b, 1996a and b, 1997a-d). Statistical
analysis was carried out using NCSS 6.01 statistical software
(Kaysville, Utah, and Deltasoft, Meylan 38200, France). Various
statistical tests were used depending on the type (nominal or
ordinal) and distribution (normal or not) of the variables.
Consequently, parametric or non-parametric tests were applied,
including the chi-square test, Student's t-test, Kruskal-Wallis test,
Mann-Whitney U-test and the calculation of correlation coeffi-
cients (Spearman's, Kendall's and Pearson's tests).
RESULTS
Patterns of VLA2 distribution in cells and tissues
Patterns of immunoreaction were heterogeneous, as shown in
Figures 1-3. Anti-VLA2 reacted with epithelial cells but not in
Size (mm)
< 10
11-20
21-30
> 30
< 15
.15
Gradea
SBR (Elston's)
1
2
3
SBRM (Le Doussal's)
1
2
3
4
5
Group
Group II
NPI (Galea)
1 (< 3.4)
2 (3.4-5.4)
3 (> 5.4)
Histological types
Ductal
Lobular
Node status
Node positive
Node negative
Feulgen staining
Diploid
Aneuploid
No hyperploidy
Hyperploidy
46 18
68 17
2213 9
2
85 29
64 17
26
79
34
11
41
43
38
5
95
43
59
15
18
16
21
10
3
16
12
7
2
%2 = 2.72
P = 0.44 (NS)
%2 = 0.52
P=0.47
%2 = 4.78
P = 0.09 (NS)
P2 = 2.43
P= 0.66 (NS)
31 X2= 1.13
9 P= 0.29 (NS)
21
15
4
x2 = 0.61
P = 0.74 (NS)
110 38 X2=0.71
37 9 P = 0.40 (NS)
93 28 X2=0.45
55 20 P= 0.50 (NS)
49
69
21
17
16
23
6
33
%2 = 0.02
P=0.89
%2 = 0.12
P = 0.73 (NS)
aStatistics calculated using the Mann-whitney test. SBR, Scarff-Bloom-
Richardson score; SBRM, SBR modified.
tumour stroma. The positive immunoreactions with anti-VLA, in
ductal carcinomas were not significantly different from lobular
carcinomas or from carcinomas of other types. In invasive ductal
carcinomas (grade I-III), staining was variable, but variations in
positive immunoreactions observed in individual tumour were
independent of tumour dedifferentiation.
VLA2 quantitative immunodetection
Only 23.5% (48 of 204) of the tumours were VLA, positive. The
distribution of anti-VLA2-positive staining as evaluated by densit-
ometry on tissue sections is shown in Figure 4. Positive tumour
surfaces stained by anti-VLA2 ranged from 3% to 40% (mean
8.75%; s.d. 7.2).
VLA2 expression and clinicopathological data
VLA2-immunostained surface evaluated by image analysis was
independent of the patients' age, tumour size, histological type,
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Table 2 VLA2 immunocytochemical expression and other immunocytochemical markers in breast carcinomas
Quantitative VLA2 VLA2 =0 VLA2 >0 Statistical
immunocytochemistry (all tumours) (negative tumours) (positivetumours) tests
(positive surface) n = 203 n = 155/203 n = 48/203
t p
Ki 67/MIB1 (%)
All tumours
Positive tumours
c-erbB-2 (%)
All tumours
Positive tumours
p53 (%)
All tumours
Positive tumours
bcl-2 (%)
All tumours
Positive tumours
E cadherin (%)
All tumours
Positive tumours
CD44 v6 (%)
All tumours
Positive tumours
CD31 (%)
All tumours
Positive tumours
Cathepsin D (%)
All tumours
Positive tumours
P-gp (%)
All tumours
Positive tumours
ER (%)
All tumours
Positive tumours
PR (%)
All tumours
Positive tumours
pS2 (%)
All tumours
Positive tumours
VCAM (%)
All tumours
Positive tumours
VLA3 (%)
All tumours
Positive tumours
ELAM (%)
All tumours
Positive tumours
14.26 (11.30)
14.26 (11.30)
18.85 (15.18)
19.43 (15.04)
4.22 (11.86)
18.23 (18.89)
17.31 (17.40)
22.21 (16.72)
30.23 (18.28)
33.33 (16.27)
14.04 (14.62)
17.05 (14.43)
10.95 (6.55)
11.01 (6.52)
19.3 (11.7)
29.3 (14.3)
2.52 (4.16)
6.21 (4.44)
11.71 (14367)
16.98 (14.48)
11.40 (15.12)
18.52 (15.47)
3.76 (6.32)
8.69 (7.04)
2.59 (4.57)
6.33 (5.24)
8.18 (11.16)
13.79 (11.51)
6.54 (8.73)
11.758 (8.69)
15.11 (11.84)
15.11 (11.84)
18.56 (15.92)
19.16 (15.82)
4.79 (13.11)
21.20 (20.51)
17.10 (17.43)
21.01 (17.06)
29.71 (18.58)
33.11 (16.48)
13.66 (14.93)
16.78 (14.88)
11.18 (6.55)
11.25 (6.51)
20.9 (12.4)
30.9 (17.5)
2.19 (3.66)
5.93 (3.76)
12.31 (15.11)
18.00 (15.22)
11.15 (15.14)
18.19 (15.69)
3.66 (6.44)
9.33 (7.28)
1.62 (2.78)
4.66 (2.85)
6.40 (8.97)
11.33 (9.31)
5.19 (7.12)
10.31 (6.92)
11.54 (8.96)
11.54 (8.96)
2.22
2.22
19.82 (12.48)
20.35 (12.20)
2.40 (6.07)
9.58 (9.06)
17.98 (17.46)
26.97 (14.55)
31.97 (17.38)
34.02 (15.76)
15.27 (13.63)
17.88 (13.06)
0.51
0.48
1.75
2.68
0.30
2.00
0.75
0.33
0.70
0.45
10.21 (6.58)
10.21 (6.58)
0.88
0.95
17.6 (11.2)
24.3 (15.2)
3.56 (5.37)
6.84 (5.75)
9.77 (11.52)
13.79 (11.48)
12.23 (15.17)
19.57 (14.98)
4.08 (5.97)
7.26 (6.36)
5.70 (7.16)
9.43 (7.04)
13.38 (14.89)
19.80 (14.14)
1.44
1.44
1.65
0.73
0.034
0.034
0.615
0.632
0.091
0.012
0.763
0.055
0.460
0.740
0.490
0.654
0.386
0.351
0.161
0.161
0.109
0.473
1.23 0.227
1.71 0.098
0.43 0.669
0.43 0.667
0.42 0.677
1.34 0.189
3.85 0.001
3.50 0.001
2.69
2.76
10.92 (11.65)
14.97 (11.18)
3.23
2.28
0.012
0.010
0.003
0.030
Numbers in parentheses are standard deviation values.
tumour differentiation and ploidy, histoprognostic grades, lymph
node status and Nottingham prognostic index. No significant
difference between these parameters and anti-VLA2-positive
or -negative reaction was observed. Moreover, there was no
significant relationship between VLA2 expression evaluated by
quantitative immunocytochemistry at various cut-off points (5%,
10%, 15%) and any of the clinicopathological parameters studied
(Table 1).
Correlation of VLA2 expression with quantitative
immunodetection
Distribution
The distribution of the antigens, investigated using the same
method as that for VLA2 on serial sections, was first studied by
calculation of the mean positive (immunostained) surface (%) in
VLA2-positive (48 of204) and -negative (156 of204) subsets.
The results ofquantitative evaluation ofgrowth fraction (MIB1)
and immunoreaction with anti-p53, anti-bcl-2, anti-c-erbB-2
protein, anti-cathepsin D, anti-CD31, anti-CD44v, anti-cadherin,
anti-VCAM, anti-ELAM, anti-VLA3, anti-P-gp, anti-ER and -PR
antigenic sites, and anti-pS2 in VLA2 -positive and -negative
tumours are shown in Table 2.
Correlation (Spearman's and Kendall's tests)
VLA2 expression in breast carcinomas was independent ofmost of
the other antigens investigated (Table 3). However, a significant
correlation was observed between VLA2 immunohistochemical
expression and that of P-gp, VCAM, ELAM and VLA3 (Tables 3
and 4) and was inversely correlated with cathepsin D.
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Table 3 Correlation of quantitative immunocytochemical assays of VLA2 to
that of other antigens investigated on consecutive sections of frozen blocks,
automated (Ventana) procedure and image analysis (SAMBA)
VLA2 immunocytochemical
expression
r= - 0.298
r= 0.345
r= 0.499
r= 0.193
r= 0.425
P < 0.001 (Spearman)
P< 0.01 (Spearman)
P < 0.001 (Spearman)
P < 0.01 (Spearman)
P = 0.036 (Spearman)
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
DISCUSSION
Mortality in breast cancer is related to the development of blood-
borne metastases. Tumour metastases require the release of cells
from the primary site, migration through the extracellular matrix
into the microvasculature and finally arrest in distant organ (Zutter
and Santoro, 1990). Various molecules, especially adhesion mole-
cules, are involved at the different steps of the metastatic process
and are expressed on tumour cells or released in the extracellular
compartment (Zutter and Santoro, 1990; Albelda, 1993; Pignatelli
and Vessey, 1994). Thus their immunodetection in tissue sections
may be a relevant tool useful in clinical practice to identify
patients with significant risk of developing metastatic disease,
promoted by the variations in the expression ofthe adhesive mole-
cules. However, the practical relevance of immunohistochemistry
can be determined provided that the technical procedures are as far
as possible standardized and provided that methodological bias are
optimally reduced.
Methodological bias may result from several factors. Firstly,
tissue fixation and paraffin embedding may be the source of
antigen damage. Although recent advances in immunohistochem-
istry have shown the suitability of archival paraffin tissue blocks
for immunodetection after antigen retrieval (microwave), the
freezing oftissue blocks, when possible, basically does not modify
the structure of antigens in tissues. Secondly, inconsistencies may
result from variations in the immunohistochemical methods used.
In this regard, an automated device rather than in-house manual
procedures provides a better guarantee of quality control, particu-
larly with regard to reproducibility. Finally, analytical bias may
result from the method used for the evaluation of the results.
Semiquantitative analysis of the immunoprecipitates in tissue
sections is convenient, rapid and cost effective, but its reliability
hinges on observers' experience and reproducibility. Although
semiquantitative evaluation is obviously sufficient to differentiate
negative vs positive reaction, it is not accurate enough to evaluate
intermediate patterns of staining. In contrast, quantitative analysis
by computerized processing of digitized microscopic images
provides more objective data, and variations in staining are more
accurately evaluated. In addition, the numeric values ofparameters
are more suitable for statistical analysis. In the present study, we
evaluated VLA, in optimal technical conditions using frozen tissue
sections, automated immunohistochemistry and computerized
analysis of digitized microscopic images, as previously used for
other molecules (Charpin et al, 1988a and b, 1994, 1995a and b,
1996b, 1997a-d).
Adhesion molecules are involved in the cascade ofevents ofthe
metastatic disease. Some are involved in cell-cell adhesion or in
cell adhesion to epithelial basement membrane. Some are involved
in adhesion to extracellular matrix and others in adhesion to the
vessel wall either to activate endothelial cells or to increase
binding to vessel basement membrane. VLA, which is an o2 P1
integrin acting as a receptor for collagen and laminin, is involved
in cell binding to epithelial basement membrane and also to the
vessel basement membrane. These adhesive properties of tumour
cells expressing VLA, promote the development of metastases as
shown by experimental data (Chan et al, 1991) and facilitate adhe-
sion to the vessel wall. However, the decreased expression of
VLA, in human carcinomas (Zutter et al, 1990); Pignatelli et al,
1991a and b; Stamp and Pignatelli, 1991; Arihiro et al, 1993;
Bonkhoff et al, 1993; Patriarca et al, 1993) is associated with
higher metastatic rate or tumour dedifferentiation. In this respect,
the VLA, expression of tumour cells in early breast carcinomas
could constitute a prognostic indicator.
Using optimal technical conditions (not comparable to previous
studies for VLA, immunodetection) in our series of breast carci-
nomas, we did not observe any significant relationship between
VLA, expression and current histoprognostic indicators, such as
tumour size, grade, type, degree of tumour aneuploidy and hyper-
ploidy, or the axillary node status and the Nottingham prognostic
index. These results suggest that in order to determine its exact
prognostic relevance, the significance of VLA, expression in
Table 4 VLA2 immunocytochemical expression and Cathepsin D in breast carcinomas
VLA2 <5% 5%< VLA2.s 10% 10% < VLA2 < 20% VLA2 > 20% Total Chi-square test
Cathepsin D < 15% 83 6 6 0 95
Percentage of line 87.3 6.3 6.3 0
Percentage of column 51.6 24 60 0
15% < Cathepsin D < 20% 25 9 1 0 35 X2 = 13.43
Percentage of line 71.4 25.7 2.9 0 P = 0.037
Percentage of column 15.5 36 10 0
Cathepsin D < 20% 53 10 3 2 68
Percentage of line 77.9 14.7 4.4 2.9
Percentage of column 32.9 40 30 100
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breast carcinomas requires further investigation, using the same
method, taking into account correlation with the patients' outcome.
The adhesive properties oftumour cells probably depend on the
expression of adhesion molecules, which may vary independently
or concomitantly. VLA2 expression by tumour in breast carci-
nomas seems to be independent of cell-cell adhesion or adhesion
to extracellular matrix, as VLA2 immunostaining was independent
of E cadherin or of CD44 v6 expression detected using the same
method (Charpin et al, 1997b and c). However, VLA2 significantly
correlated with VLA3 (P < 0.01), a receptor for fibronectin that
also belongs to the integrin group and that may have similar regu-
lation mechanisms.
We found that VLA, expression was inversely correlated with
cathepsin D (Spyratos et al, 1989) expression in tumour sections,
suggesting that the decreased capacity of tumour cells to bind to
basement membrane is associated with an increased capacity of
tumour cell migration in the extracellular matrix, facilitated by
proteases that they produce. Thus, VLA2 and D cathepsin seem to
concomitantly promote tumour progression.
Angiogenesis in breast carcinomas favours tumour growth and
facilitates entry into the circulation (Folkman, 1971; Liotta et al,
1974), and vessel counts and immunohistochemical labelling of
vessels and endothelial cells have been shown to be endowed with
some clinical relevance (Weidner, 1991; Charpin et al, 1997a). Our
results show that VLA2 immunocytochemical expression is indepen-
dent of that of CD31, which reflects tumour stromal angiogenesis
(Charpin et al, 1995b). However, VLA2 was found to correlate
(P < 0.01) with the expression of VCAM (IGSF) and ELAM
(E-selectin) in tumours reflecting the activation of endothelial cells.
This suggests that the increased expression of ELAM or VCAM
molecules, which are receptors for ligands expressed on the surface
oftumourcells, such as Sialyl Lewisx determinants (Walz etal, 1990;
Tiemeyer et al, 1991) or VLA4 (Albelda et al, 1990; Elices et al,
1990; Gelhsen et al, 1992), correlates with the capacity of tumour
cells, to bind vessel basement membranes through VLA2 expression.
Some experimental studies have shown that collagen-induced
morphogenesis and expression of o2 integrin subunit is inhibited
in c-erbB-2-transfected MTSV1-7 human mammary epithelial
cells (D'Souza et al, 1993), suggesting that in human breast carci-
nomas the expression of c-erbB-2 product could correlate with
integrin expression. However, in our study, VLA2 / ox2 1 integrin
did not significantly correlate with c-erbB-2, both molecules being
detected according to the same immunohistochemical procedures
on consecutive sections.
Recently, we also used this method to detect p53, bcl-2 and
Ki67 antigens in breast carcinomas (Charpin et al, 1996a, 1997b
and d). These antigens have been reported to correlate with tumour
growth and tumour cell proliferative activity. Similar to C-erbB2
expression, the expression of these molecules did not correlate
with VLA2 expression, suggesting that cell proliferation and adhe-
sive properties are regulated differently.
In conclusion, our results show that VLA2 immunohisto-
chemical expression in breast carcinomas is independent of most
current histoprognostic indicators and of the tumour cells expres-
sion of some adhesion molecules, such as E cadherins. However,
VLA, expression correlates with the expression in tumours of
adhesion molecules of the same family, such as VLA3 integrin or
another family, such as E-selectin (ELAM) or IGSF (VCAM).
The prognostic significance of VLA2 expression in tumours
remains to be demonstrated by correlations with the patients'
outcome.
ACKNOWLEDGEMENTS
This study was supported by grants from la Fondation pour la
Recherche Medicale and Aix Marseille II University (BQR 1997).
REFERENCES
Albelda SM (1993) Role of integrins and other cell adhesion molecules in tumor
progression and metastasis. Lab Invest 68: 4-17
Arihiro K, Inai K, Kurihara K, Takeda S, Kaneko M, Kuroi K and Toge T (1993)
Loss of VLA-2 collagen receptor in breast carcinoma, facilitating invasion and
metastasis. Jpn J Cancer 84: 726-733
Bonkhoff H, Stein U and Remberger K (1993) Differential expression ofat6 and ct2
very late antigen integrins in the normal, hyperplastic, and neoplastic prostate:
simultaneous demonstration ofcell surface receptors and their extracellular
ligands. Hum Pathol 24: 243-248
Brugal G, Garbay C, Giroud-Adhel D (1979) A double scanning microphotometer
for image analysis: hardware, software and biomedical application.
J Histochem Cvtochem 27: 144
Chan BMC, Matsuura N, Takada Y, Zetter BR and Hemler ME (1991) In vitro and
in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells.
Science 251: 1600-1602
Charpin C, Andrac L, Vacheret H, Habib MC, Devictor B, Lavaut MN, Toga M
(1988a) Multiparametric evaluation (SAMBA) ofgrowth fraction (monoclonal
Ki67) in breast carcinoma tissue sections. CancerRes 48: 4368-4374
Charpin C, Martin PM, Devictor B, Lavaut MN, Habib MC and Toga M (1988b)
Multiparametric study (SAMBA 200) ofestrogen receptor
immunocytochemical assay in 400 human breast carcinomas analysis of
estrogen receptor distribution heterogeneity in tissues and correlations with
dextran coated charcoal assays and morphological data. Cancer Res 48:
1578-1586
Charpin C, Andrac L, Lavaut MN, Andonian C, Fratemo M, Devictor B, Perez-
Castillo A, Bonnier P and Piana L (1990) Image cytometry ofaneuploidy,
growth fraction (MoAb Ki-67) and hormone receptors (ER, PR)
immunocytochemical assays in breast carcinomas. Anal Cell Pathol 2:
357-371
Charpin C, Bonnier P, Piana L, Kouzhami H, Devictor B, Lavaut MN, Andrac L and
Allasia C (1992) Correlation ofnuclear organizer regions and nuclear
morphometry assessed by automatic image analysis in breast cancer with
aneuploidy, Ki67 immunostaining, histopathologic grade and lymph node
involvement. Pathol Res Pract 188: 1009-1017
Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C,
Horschowski N and Piana L (1994) Quantitative immunocytochemical assays
ofP-glycoprotein in breast carcinomas: correlation to messenger RNA
expression and to immunohistochemical prognostic indicators. JNatl Cancer
Inst 86: 1539-1545
Charpin C, Devictor B, Andrac L, Amabile J, Bergeret D, Lavaut MN, Allasia C and
Piana L (I995a) p53 quantitative immunocytochemical analysis in breast
carcinomas. Hum Pathol 26: 159-166
Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN
and Piana L (1995b) CD31 quantitative immunocytochemical assays in breast
carcinomas: correlation with current prognostic factors. Am J Clin Pathol 103:
443-448
Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN, Allasia C and
Bonnier P (1996a) Prognostic value of Ki 67/MIB 1 automated and quantitative
immunolabelling in primary operable breast carcinomas. Int J Oncol 9:
337-344
Charpin C, Garcia S, Bouvier C, Andrac L, Devictor B, Lavaut MN, Allasia C,
Bonnier P, Piana L (1996b) Quantitative immunocytochemical assays on frozen
sections ofp53. Correlation to the follow-up ofpatients with breast
carcinomas. Am J Clin Pathol 106: 640-646
Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN,
Allasia C (1997a) CD31/PECAM automated and quantitative
immunocytochemical assays in breast carcinomas. Correlation with patient
follow-up. Am J Clin Pathol 107: 534-541
Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut MN and
Allasia C (1997b) Automated and quantitative immunocytochemical assays of
CD44v6 in breast carcinomas. Hum Pathol 28: 289-296
Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R and Lavaut MN
(1997c) E-Cadherin quantitative immunocytochemical assays in breast
carcinomas. J Pothol 181: 294-300
C Cancer Research Campaign 1998 British Journal ofCancer(1998) 77(12), 2274-22802280 C Charpin etal
Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN and Allasia C
(I997d) Automated and quantitative immunocytochemical assays of Bcl-2
protein in breast carcinomas. BrJ Cancer 76: 340-346
De Strooper B, Van der Schuerer D, Jaspers M, Saison M, Spaepen M, Val Leuven F,
Van Den Berghe H and Cassiman JJ (1989) Distribution ofthe Pi subgroup of
the integrins in human cells and tissues. J Histochem Cvtochem 37: 299-307
D'Souza B, Berdichevsky F, Kyprianou N and Taylor-Papadimitriou J (1993)
Collagen-induced morphogenesis and expression in the a2-integrin subunit is
inhibited in c-erb B2-transfected human mammary epithelial cells. Oncogene 8:
1797-1806
Elices MJ, Osborn L, Takada Y, Crouse C, Luhowski JS, Hemler ME and Lobb RR
(1990) VCAM-1 on activated endothelium interacts with the leucocyte integrin
VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:
577-584
Elston CW and Ellis 10 (1991) Pathological prognostic factors in breast cancer. I.
The value ofhistological grade in breast cancer: experience from a large study
with long term follow-up. Histopathology 19: 403-410
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med285:
1182-1186
Galea MH, Blamey RW and Elston CE (1992) The Nottingham prognostic index in
primary breast cancer. Breast Cancer Res Treat 22: 207-219
Gehlsen KR, Davis GE and Sriramatao P (1992) Integrin expression in human
melanoma cells with differing invasive and metastatic properties. Clin Exp
Metast 10: 111-120
Grogan TM, Casey TT, Miller PC, Rangel C, Nunnery D and Nagle R (1993)
Automation of immunohistochemistry. Adv Pathol Lab Med 6: 253-283
Grogan TM, Rangel C, Rimsza L, Bellamy W, Martel R, McDaniel D, McGraw B,
Richards W, Richards L, Rodgers P, Rybski J, Showalter W and Zeheb R
(1995) Kinetic-mode, automated double-labeled immunohistochemistry and in
situ hybridization in diagnostic pathology. Adv Pathol Lab Med 8: 79-99
Hynes RO (1987) Integrins, a family ofcell surface receptors. Cell 48: 549-555
Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F and Brunet M
(1989) Prognostic value of histologic grade nuclear components of
Scarff-Bloom-Richardson (SBR): an improved score modification based on a
multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:
1914-1921
Liotta LA, Kleinerman J and Saidel GM (1974) Quantitative relationships of
intravascular tumor cells, tumors vessels, and pulmonary metastases following
tumor implantation. Cancer Res 34: 997-1004
Patriarca C, Roncalli M, Gambacorta M, Cominotti M, Coggi G and Viale G (1993)
Patterns of integrin common chain ,B1 and collagen IV immunoreactivity in
hepatocellular carcinoma correlations with tumour growth rate, grade and size.
J Pathol 5: 5-11
Pignatelli M and Vessey CJ (1994) Adhesion molecules: novel molecular tools in
tumor pathology. Hum Pathol 25: 849-856
Pignatelli M, Smith MEF and Bodmer WF (1991la) Low expression ofcollagen
receptors in moderate and poorly differentiated colorectal adenocarcinomas.
BrJ Cancer 61: 636-638
Pignatelli M, Hanby AM and Stamp GWH (199lb) Low expression of ,B1, a2 and
a3 subunits of VLA integrins in malignant mammary tumors. J Pathol 165:
25-32
Ruoslahti E (1991) Integrins. J Clin Invest 87: 1-5
Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki B (1993)
Tumour progression and metastatic behaviour in vivo correlates with integrin
expression on melanocytic tumours. JPathol 170: 429-434
Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouesse J, Maudelonde T, Brunet
M, Andrieu C, Desplaces A and Rochefort H (1989) Cathepsin D: an
independent prognostic factor for metastasis ofbreast cancer. Lancet 8672:
1115-1118
Stamp GWH and Pignatelli M (1991) Distribution of B11, tal, a2 and t3 integrin
chains in basal cell carcinomas. J Pathol 163: 307-313
Tiemeyer M, Swiedler SJ, Ishihara M, Moreland M, Schweingruber H, Hirtzer P and
Brandley BK (1991) Carbohydrate ligands for endothelial-leukocyte adhesion
molecule 1. Proc NatlAcad Sci USA 88: 1138-1142
Walz G, Aruffo A, Kolanus W, Bevilacqua M and Seed B (1990) Recognition by
ELAM- ofthe Sialyl-Lex determinant on myeloid and tumor cells. Science
250: 1132-1135
Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumor angiogenesis and
metastasis: correlation in invasive breast carcinoma. N Engl JMed 324: 1-8
Zetter BR (1993) Adhesion molecules in tumor metastasis. CancerBiology 4:
219-229
Zutter MM and Santoro SA (1990) Widespread histologic distribution of the a2f3 1
integrin cell surface collagen receptor. Am JPathol 137: 113-120
Zutter MM, Mazoujian G and Santoro SA (1990) Decreased expression of integrin
adhesive protein receptors in adenocarcinoma ofthe breast. Am J Pathol 137:
863-870
British Journal ofCancer (1998) 77(12), 2274-2280 C Cancer Research Campaign 1998